[1] Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer[J]. N Engl J Med, 2010, 363(1): 2435.
[2] de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis[J]. Lancet Oncol, 2012, 13(6): 607615.
[3] Blomberg M, Nielsen A, Munk C, et al. Trends in head and neck cancer incidence in Denmark, 19782007: focus on human papillomavirus associated sites[J]. Int J Cancer, 2011, 129(3): 733741.
[4] Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States[J]. J Clin Oncol, 2011, 29(32): 42944301.
[5] Rettig E, Kiess AP, Fakhry C. The role of sexual behavior in head and neck cancer: implications for prevention and therapy[J]. Expert Rev Anticancer Ther, 2015, 15(1): 3549.
[6] Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 20092010[J]. JAMA, 2012, 307(7): 693703.
[7] Saba NF, Goodman M, Ward K, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results programbased analysis[J]. Oncology, 2011, 81(1): 1220.
[8] AlSwiahb JN, Huang CC, Fang FM, et al. Prognostic impact of pl6, p53,epidermalgrowth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nutchewing area[J]. Arch Otolaryngol Head Neck Surg, 2010, 136(5): 502508.
[9] Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papillomavirus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer[J]. Clin Cancer Res, 2010, 16(7): 21382146.
[10] Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16immunopositive but HPV DNAnegative oropharyngeal carcinomas[J]. Int J Cancer, 2014, 134(10): 23662372.
[11] Boucek J, Mrkvan T, Chovanec M, et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck[J]. J Cell Mol Med, 2010, 14(12): 426433.
[12] Wamsom D, Light E, Thomas D, et al. Infiltrating lymphocytes and human papillomavirus16associated oropharyngeal cancer[J]. Laryngoscope, 2012, 122(1): 121127.
[13] Lukesova E, Boucek J, Rotnaglova E, et al. High level of tregs is a positive prognostic marker in patients with HPVpositive oral and oropharyngeal squamous cell carcinomas[J]. Biomed Res Int, 2014, 2014: 303929.
[14] Badoual C, Hans S, Merillon N, et al. PD1expressing tumorinfiltrating T cells are a favorable prognostic biomarker in HPVassociated head and neck cancer[J]. Cancer Res, 2013, 73(1): 128138.
[15] Liang X, Zheng M, Jiang J, et al. Hypoxiainducible factor1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma[J]. Oral Oncol, 2011, 47(2): 9297.
[16] Zhu GQ, Tang YL, Li L, et al. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma[J]. Clin Cancer Res, 2010, 16(19): 47324741.
[17] Rahimi AS, Wilson DD, Saylor DK, et al. p16,CyclinD1,and HIF1αpredict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensitymodulated radiation therapy[J]. Int J Otolaryngol, 2012, 2012: 685951.
[18] Song X, Sturgis EM, Liu J, et al. MicroRNA variants increase the risk of HPVassociated squamous cell carcinoma of the oropharynx in never smokers[J]. PLoS One, 2013, 8(2): e56622.
[19] Lajer CB, Nielsen FC, FriisHansen L, et al. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study[J]. Br J Cancer, 2011, 104(5):830840.
[20] Hui AB, Lin A, Xu W, et al. Potentially prognostic miRNAs in HPVassociated oropharyngeal carcinoma[J]. Clin Cancer Res, 2013, 19(8): 21542162.
[21] Guan X, Sturgis EM, Song X, et al. PremicroRNA variants predict HPV16positive tumors and survival in patients with squamous cell carcinoma of the oropharynx[J]. Cancer Lett, 2013, 330(2): 233240.
[22] Moore EJ, Henstrom DK, Olsen KD, et al. Transoral resection of tonsillar squamous cell carcinoma[J]. Laryngoscope, 2009, 119(3): 508515.
[23] Park YM, Lee JG, Lee WS, et al. Feasibility of transoral lateral oropharyngectomy using a robotic surgical system for tonsillar cancer[J]. Oral Oncology, 2009, 45(8): e6266.
[24] Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines[J]. Hum Vaccin, 2011, 7(2): 161169.
[25] Vermorken JB, SthlmacherWilliams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck (SPECTRUM): an openlabel phase 3 randomisedtrial[J]. Lancet Oncol, 2013, 14(8): 697710.
[26] Stenner M, Yosef B, Huebbers CU, et al. Nuclear translocation of betacatenin and decreased expression of epithelial cadherin in human papillomaviruspositive tonsillar cancer: an early event in human papillomavirusrelated tumour progression?[J]. Histopathology, 2011, 58(7): 11171126. |